The information age has produced a generation of young people concerned about their health, but distrustful of big brands – and that includes the pharmaceutical industry.
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker and awards judge Heather Moses – head of medical affairs at Roche – what she is looking for in winning patient init
